On June 17, 2024, Exicure, Inc., a biotechnology company historically focused on nucleic acid therapies, reported its financial results for the first quarter ended March 31, 2024. The company, which is incorporated in Delaware and listed on the Nasdaq Stock Market under the symbol XCUR, disclosed a significant decrease in cash and cash equivalents from $0.8 million at the end of December 2023 to $0.4 million by March 31, 2024, further declining to approximately $0.2 million by May 31, 2024. To address its funding needs, Exicure received a $0.7 million loan from DGP Co., Ltd., a major stockholder. The loan carries a 6.0% annual interest rate and matures ten months from issuance. Exicure's revenue for the quarter included an initial payment of $0.5 million from a patent license agreement for the development of cavrotolimod...Show More

On June 17, 2024, Exicure, Inc., a biotechnology company historically focused on nucleic acid therapies, reported its financial results for the first quarter ended March 31, 2024. The company, which is incorporated in Delaware and listed on the Nasdaq Stock Market under the symbol XCUR, disclosed a significant decrease in cash and cash equivalents from $0.8 million at the end of December 2023 to $0.4 million by March 31, 2024, further declining to approximately $0.2 million by May 31, 2024. To address its funding needs, Exicure received a $0.7 million loan from DGP Co., Ltd., a major stockholder. The loan carries a 6.0% annual interest rate and matures ten months from issuance. Exicure's revenue for the quarter included an initial payment of $0.5 million from a patent license agreement for the development of cavrotolimod as a potential hepatitis treatment. The company reported no R&D expenses, reflecting a halt in clinical and preclinical activities, and a decrease in G&A expenses due to reduced operations. The net loss for the quarter was $0.8 million, a significant reduction from the $4.4 million net loss in the same period of the previous year. Exicure's management has expressed concern over the sufficiency of its cash to fund operations and is actively seeking additional financing to continue operations and explore strategic alternatives to maximize stockholder value.